Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

← catalyst calendar

NCT06269133 · readout in 224 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

—

Status

Active, not recruiting

Study type

Observational

Enrollment

1,000estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-02-21

actual

When the study began enrolling

Primary completion

2027-03-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-06-23

estimated

The whole study's end, after follow-up

First posted

2024-02-21

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Non-small Cell Lung Cancer

Interventions

Drug: REGN2810 — also filed as LIBTAYO®, cemiplimab
Other: Platinum-doublet chemotherapy